Genitourinary Oncology News | GU Oncology Now

AMPLITUDE: Niraparib, Abiraterone Acetate, Prednisone for mCSPC Patients With HRR Alterations

AMPLITUDE: Niraparib, Abiraterone Acetate, Prednisone for mCSPC Patients With HRR Alterations

Gerhardt Attard, MD, PhD, reviews the outcomes of the phase 3 AMPLITUDE trial, which investigated the combination of niraparib with abiraterone acetate plus prednisone for the treatment of patients with mCSPC with HRR gene alterations.

Dr. Attard explores how the study’s results compare with prior PARP inhibitor data in the metastatic castration-resistant setting, and how the addition of niraparib differed across specific HRR alterations.

Advertisement

Latest News

Addressing Real-World Inequities in mHSPC Treatment

Addressing Real-World Inequities in mHSPC Treatment

Umang Swami, MDmCSPC | June 24, 2025

Drs. Swami and Ciuro discuss efforts to reduce disparities in the real-world application of mHSPC intensified therapy.

Human First, Patient Second: Rethinking Cancer Care Systems

Human First, Patient Second: Rethinking Cancer Care Systems

Christopher Wallis, MD, PhD, FRCSCProstate Cancer | June 24, 2025

The panel concludes with a candid discussion about the most urgent changes that could improve cancer care today.

Proactive, Not Reactive: Introducing Palliative Care Without Fear

Proactive, Not Reactive: Introducing Palliative Care Without Fear

Christopher Wallis, MD, PhD, FRCSCProstate Cancer | June 24, 2025

The panel explores the importance of introducing palliative care discussions earlier in the treatment journey.

The Price of Pills and the Weight of Words: Addressing Financial Barriers

The Price of Pills and the Weight of Words: Addressing Financial Barriers

Christopher Wallis, MD, PhD, FRCSCProstate Cancer | June 24, 2025

The panel explores the overlooked burden of financial toxicity and proactively raising the topic with patients.

Between the Lines: Listening, Trust, and the Real-Life Cost of Cancer

Between the Lines: Listening, Trust, and the Real-Life Cost of Cancer

Christopher Wallis, MD, PhD, FRCSCProstate Cancer | June 24, 2025

The panel explores how clinicians can build trust with patients from diverse backgrounds and ensure care is patient-centered.

Trials and Trust: Offering Options Without Eroding Confidence

Trials and Trust: Offering Options Without Eroding Confidence

Christopher Wallis, MD, PhD, FRCSCProstate Cancer | June 24, 2025

The panel explores how clinicians can introduce clinical trial options while maintaining trust in the face of uncertainty.

Beyond the Diagnosis: Humanizing the First Oncology Visit

Beyond the Diagnosis: Humanizing the First Oncology Visit

Christopher Wallis, MD, PhD, FRCSCProstate Cancer | June 24, 2025

The panel explores the emotional weight of a cancer diagnosis and the importance of empathetic communication.

Comparing Adjuvant Platinum Plus Paclitaxel to Platinum Plus 5-FU in High-Risk Penile Cancer

Comparing Adjuvant Platinum Plus Paclitaxel to Platinum Plus 5-FU in High-Risk Penile Cancer

Jessica GangaTesticular, Penile, and Rare Malignancies | June 20, 2025

Researchers investigated the efficacy of platinum plus 5-FU in the treatment of patients with high-risk penile cancer.

HER2 and ERBB2 Found in Over 50% of Samples in aUC Study

HER2 and ERBB2 Found in Over 50% of Samples in aUC Study

Emily MenendezAdvanced Urothelial Carcinoma | June 19, 2025

These findings highlight the need for continued development and refinement of standardized HER2 testing methods.

CAN-2409, Valacyclovir Added to Standard of Care Reduces Risk of Recurrence or Death in Prostate Cancer Patients

CAN-2409, Valacyclovir Added to Standard of Care Reduces Risk of Recurrence or Death in Prostate Cancer Patients

Emily MenendezLocalized | June 19, 2025

Almost 30% of patients will experience recurrence while undergoing EBRT that will require ADT and salvage therapies.

Avelumab Plus Sacituzumab Govitecan as a First-Line Therapy for Patients With Advanced Bladder Cancer: Interim Analysis

Avelumab Plus Sacituzumab Govitecan as a First-Line Therapy for Patients With Advanced Bladder Cancer: Interim Analysis

Jessica GangaAdvanced Urothelial Carcinoma | June 17, 2025

Avelumab plus sacituzumab govitecan may improve PFS in patients with advanced bladder cancer.

Alternatives to Cystoscopy Remain Only Adjuncts and Not Replacements

Alternatives to Cystoscopy Remain Only Adjuncts and Not Replacements

Leah LawrenceUrothelial Carcinoma Diagnostics | June 17, 2025

Although research into urine- and image-based alternatives continues, there is no established replacement for cystoscopy.

Advertisement

Advertisement

Editorial Advisory Board

Brian Rini, MD, FASCOEditor | Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center

Thomas Powles, MBBS, MRCP, MDEditor | Director, Barts Cancer Centre at St. Bartholomew's Hospital

Katy Beckermann, MD, PhDEditor | Medical Director of GU Clinical Research at Tennessee Oncology

Christopher Wallis, MD, PhD, FRCSCAssistant Professor of Urology | University of Toronto

Akhil Abraham Saji, MDEditor | Urologist at Swedish Health Services

David Ambinder, MDEditor | Urology Resident at New York Medical College/Westchester Medical Center

The Uromigos Live and Unplugged 2024

The Uromigos Live & Unplugged 2024

The Uromigos Live & Unplugged 2024

The Uromigos Live & Unplugged 2024 took place September 27-29 in Nashville, Tennessee.

This meeting was the third annual in-person event hosted by Thomas Powles, MD, and Brian Rini, MD, FASCO, in partnership with Mashup Media, featuring expert panels and audience discussion around the latest data in genitourinary oncology and vision for the future.

GU Oncology Now delivers the latest news in clinical trials, conference coverage, and more, highlighting advancements in genitourinary oncology treatments and tech.

Get research and breaking news straight to your inbox.

Expert Interviews

Teaching TURBT Over 5G: Integrating XR Headsets Into Urologic Practice

Teaching TURBT Over 5G: Integrating XR Headsets Into Urologic Practice

Evan Kovac, MDProstate Cancer | May 19, 2025

Dr. Evan Kovac speaks about his pioneering work with extended reality display technology in urologic surgery and education.

Bladder Cancer Without Cystectomy: Dr. Alexandre Zlotta on the Maturation of Trimodality Therapy

Bladder Cancer Without Cystectomy: Dr. Alexandre Zlotta on the Maturation of Trimodality Therapy

Alexandre Zlotta, MDMuscle Invasive Urothelial Carcinoma | May 15, 2025

Dr. Zlotta discusses the current state and future of bladder-sparing therapy in MIBC, including how to best select patients.

From VEGF to HIF-2 Targeting Drugs: Dr. James Brugarolas’ Journey to Transforming Kidney Cancer Treatment

From VEGF to HIF-2 Targeting Drugs: Dr. James Brugarolas’ Journey to Transforming Kidney Cancer Treatment

James “Jim” Brugarolas, MD, PhDRenal Cell Carcinoma | April 22, 2025

Dr. Brugarolas reflects on his lab's role in developing HIF-2 inhibitors and his ongoing work to improve patient outcomes.

Bladder-Sparing Innovations in MIBC: Dr. Elizabeth Plimack on the RETAIN Approach and Its Future

Bladder-Sparing Innovations in MIBC: Dr. Elizabeth Plimack on the RETAIN Approach and Its Future

Elizabeth Plimack, MD, MS, FASCOMuscle Invasive Urothelial Carcinoma | March 17, 2025

Dr. Plimack details RETAIN, from early findings with neoadjuvant ddMVAC to the evolution of RETAIN-1 and RETAIN-2.

Precision in Prostate Cancer: Dr. Amir Lebastchi on Tailoring Focal Therapy for Optimal Outcomes

Precision in Prostate Cancer: Dr. Amir Lebastchi on Tailoring Focal Therapy for Optimal Outcomes

Akhil Abraham Saji, MDLocalized | January 14, 2025

Drs. Saji and Lebastchi explore focal therapy, covering its historical evolution, techniques, and energy modalities.

Ahmed E. Ghazi – Revolutionizing and Scaling Surgical Training Through Simulation Models

Ahmed E. Ghazi – Revolutionizing and Scaling Surgical Training Through Simulation Models

David Ambinder, MDLocalized | January 6, 2025

Dr. Ghazi is recognized as a pioneer in patient-specific surgical simulation, using state-of-the-art techniques in surgery.

The Uromigos

Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD

Episode 428: ASCO 2025 Recap

Episode 428: ASCO 2025 Recap

Dr. Silke Gillessen joins the show to discuss highlights from the ASCO 2025 Annual Meeting with Brian and Tom.

# Posted on June 16, 2025

Episode 427: Emerging Data in Non-Muscle Invasive Bladder Cancer

Episode 427: Emerging Data in Non-Muscle Invasive Bladder Cancer

Dr. Joshua Meeks joins the podcast to give a stellar overview of emerging data in the NMIBC space.

# Posted on June 16, 2025

# Uromigos-Bladder Cancer

Episode 426: ASCO 2025 - AMPLITUDE Phase 3 of PARPi in mHSPC

Episode 426: ASCO 2025 - AMPLITUDE Phase 3 of PARPi in mHSPC

Dr. Gerhardt Attard discusses practice-changing data from AMPLITUDE, and the history of PARP inhibitor use.

# Posted on June 9, 2025

# Uromigos-ASCO

Conference Coverage

Live meeting highlights

Comparing Adjuvant Platinum Plus Paclitaxel to Platinum Plus 5-FU in High-Risk Penile Cancer

Jessica GangaTesticular, Penile, and Rare Malignancies | June 20, 2025

Researchers investigated the efficacy of platinum plus 5-FU in the treatment of patients with high-risk penile cancer.

AMPLITUDE: Niraparib, Abiraterone Acetate, Prednisone for mCSPC Patients With HRR Alterations

Gerhardt Attard, MD, PhDmCSPC | June 20, 2025

Dr. Attard explores how the study's results compare with prior data in the metastatic castration-resistant setting.

Avelumab Plus Sacituzumab Govitecan as a First-Line Therapy for Patients With Advanced Bladder Cancer: Interim Analysis

Jessica GangaAdvanced Urothelial Carcinoma | June 17, 2025

Avelumab plus sacituzumab govitecan may improve PFS in patients with advanced bladder cancer.

Ipilimumab Plus Nivolumab Outperforms SOC in OS Rates for Patients With nccRCC

Emily MenendeznccRCC | June 12, 2025

At 12 months, the OS rate for patients who received treatment with ipilimumab plus nivolumab was superior to SOC.

Video Insights

Clinical discussions with experts in the field

Network Websites

Blood Cancers Today provides hematologists and oncologists with news, education, and research relevant to their patients and practices. Featuring the latest clinical updates from all facets of the specialty, it offers thought-provoking insights and exclusive interviews from experts in the field.

MashupMD is an innovative medical news and social media aggregator. The platform is optimized to deliver rapid access to the latest headlines in health care and collections of key medical content based on what health care professionals around the world are reading and sharing.

Cancer Nursing Today delivers critical news, research, and commentary to support oncology nurses throughout their education and careers. Its goal is to advance oncology treatments and care practices and promote the nurse’s role in enhanced patient outcomes and quality of life.

DocWire News is a leading source of medical industry news for health care professionals, featuring breaking news, expert commentary, research analysis, and conference highlights. It covers a comprehensive range of clinical specialties, including cardiology, oncology, neurology, and more.

Urban Health Today is the leading independent news source that provides urban health care professionals with relevant research and policy developments that impact patients and their practices. Its coverage focuses on clinical, social, and environmental health disparities.

Powered by DocWire News

GI Oncology Now is the leading medical news resource for practicing oncologists and health care providers treating gastrointestinal malignancies, offering the latest study data and research breakthroughs related to colorectal, gastric, liver, pancreatic, and esophageal cancers.

Heme Today produces the latest news and research for hematologists and oncologists focused on blood disorders such as clotting, red and white blood cell, and iron disorders, including conference highlights, late-breaking research, interviews with leaders in the field, and more.

A medical news property for practicing oncologists treating lung malignancies, Lung Cancers Today features breaking news, commentary, expert interviews, and data analysis to inform providers on the latest research and most effective clinical practices in the lung cancers space.

Nephrology Times delivers the latest news in nephrological treatments and technologies, curating content from clinical trials, conference highlights, and perspectives from key opinion leaders, with the goal of better informing care decisions and improving patient outcomes.